Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 May;61(5):749–754. doi: 10.1038/bjc.1990.167

Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer.

W P Steward 1, J H Scarffe 1, L Y Dirix 1, J Chang 1, J A Radford 1, E Bonnem 1, D Crowther 1
PMCID: PMC1971606  PMID: 1692472

Abstract

Nine patients with progressive, metastatic disease from primary carcinoma of the colon were entered into a phase I/II study using continuous intravenous infusions of granulocyte-macrophage colony-stimulating factor (GM-CSF) and high dose melphalan (120 mg m-2). GM-CSF was given alone to six patients during the first part of the study to determine a dose that would produce a peripheral leucocyte count (WCC) greater than or equal to 50 X 10(9) 1(-1) and was initially given at 3 micrograms kg-1 day-1 and escalated to 10 micrograms kg-1 day-1 after 10 days. The infusion was discontinued when the WCC exceeded 50 X 10(9) 1(-1) and after a gap of one week, melphalan was given over 30 min. GM-CSF was recommenced 8 h later and was continued until the neutrophil count had exceeded 0.5 X 10(9) 1(-1) for greater than 1 week. One patient achieved a WCC greater than 50 X 10(9) 1(-1) with GM-CSF 3 micrograms kg-1 day-1, but the other five who entered this phase of the study required dose escalation to 10 micrograms kg-1. No toxicity attributed to GM-CSF was seen. After melphalan, the median times to severe neutropenia (less than 0.5 X 10(9) 1(-1] and thrombocytopenia (greater than 20 X 10(9) 1(-1] were 6 and 9 days respectively. The median durations of neutropenia and thrombocytopenia were 14 and 10 days respectively. All patients required intensive support with a median duration of inpatient stay of 24 days. There was one treatment related death due to renal failure. One complete and two partial remissions (33% response rate) were seen but these were of short duration (median of 10 weeks). This study demonstrates that GM-CSF given by continuous intravenous infusion produces significant increments of peripheral granulocyte counts at 3 and 10 micrograms kg-1 day-1 and is not associated with any toxicity. The duration of neutropenia and thrombocytopenia induced by high-dose melphalan appears to be reduced by the subsequent administration of GM-CSF to times which are at least as short as have been reported in historical series which have used autologous bone marrow rescue.

Full text

PDF
749

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman K. S., Griffin J. D., Elias A., Socinski M. A., Ryan L., Cannistra S. A., Oette D., Whitley M., Frei E., 3rd, Schnipper L. E. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988 Sep 8;319(10):593–598. doi: 10.1056/NEJM198809083191001. [DOI] [PubMed] [Google Scholar]
  2. Ardiet C., Tranchand B., Biron P., Rebattu P., Philip T. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases. Cancer Chemother Pharmacol. 1986;16(3):300–305. doi: 10.1007/BF00293997. [DOI] [PubMed] [Google Scholar]
  3. Bonadonna G., Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981 Jan 1;304(1):10–15. doi: 10.1056/NEJM198101013040103. [DOI] [PubMed] [Google Scholar]
  4. Brandt S. J., Peters W. P., Atwater S. K., Kurtzberg J., Borowitz M. J., Jones R. B., Shpall E. J., Bast R. C., Jr, Gilbert C. J., Oette D. H. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988 Apr 7;318(14):869–876. doi: 10.1056/NEJM198804073181401. [DOI] [PubMed] [Google Scholar]
  5. Bronchud M. H., Howell A., Crowther D., Hopwood P., Souza L., Dexter T. M. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer. 1989 Jul;60(1):121–125. doi: 10.1038/bjc.1989.234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bronchud M. H., Scarffe J. H., Thatcher N., Crowther D., Souza L. M., Alton N. K., Testa N. G., Dexter T. M. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987 Dec;56(6):809–813. doi: 10.1038/bjc.1987.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cornbleet M. A., McElwain T. J., Kumar P. J., Filshie J., Selby P., Carter R. L., Hedley D. W., Clark M. L., Millar J. L. Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. Br J Cancer. 1983 Sep;48(3):329–334. doi: 10.1038/bjc.1983.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Corringham R., Gilmore M., Prentice H. G., Boesen E. High-dose melphalan with autologous bone marrow transplant. Treatment of poor prognosis tumors. Cancer. 1983 Nov 15;52(10):1783–1787. doi: 10.1002/1097-0142(19831115)52:10<1783::aid-cncr2820521004>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  9. Davis H. L. Chemotherapy of large bowel cancer. Cancer. 1982 Dec 1;50(11 Suppl):2638–2646. [PubMed] [Google Scholar]
  10. DeVita V. T. Dose-response is alive and well. J Clin Oncol. 1986 Aug;4(8):1157–1159. doi: 10.1200/JCO.1986.4.8.1157. [DOI] [PubMed] [Google Scholar]
  11. Ekert H., Ellis W. M., Waters K. D., Tauro G. P. Autologous bone marrow rescue in the treatment of advanced tumors of childhood. Cancer. 1982 Feb 1;49(3):603–609. doi: 10.1002/1097-0142(19820201)49:3<603::aid-cncr2820490334>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  12. Frei E., 3rd Antitumor agents--dose response curve clinical and experimental considerations. Exp Hematol. 1979;7 (Suppl 5):262–264. [PubMed] [Google Scholar]
  13. Frei E., 3rd, Canellos G. P. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct;69(4):585–594. doi: 10.1016/0002-9343(80)90472-6. [DOI] [PubMed] [Google Scholar]
  14. Hartmann O., Kalifa C., Benhamou E., Patte C., Flamant F., Jullien C., Beaujean F., Lemerle J. Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Chemother Pharmacol. 1986;16(2):165–169. doi: 10.1007/BF00256169. [DOI] [PubMed] [Google Scholar]
  15. Henderson I. C., Hayes D. F., Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol. 1988 Sep;6(9):1501–1515. doi: 10.1200/JCO.1988.6.9.1501. [DOI] [PubMed] [Google Scholar]
  16. Lazarus H. M., Herzig R. H., Graham-Pole J., Wolff S. N., Phillips G. L., Strandjord S., Hurd D., Forman W., Gordon E. M., Coccia P. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol. 1983 Jun;1(6):359–367. doi: 10.1200/JCO.1983.1.6.359. [DOI] [PubMed] [Google Scholar]
  17. Leff R. S., Thompson J. M., Johnson D. B., Mosley K. R., Daly M. B., Knight W. A., 3rd, Ruxer R. L., Jr, Messerschmidt G. L. Phase II trial of high-dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma. J Clin Oncol. 1986 Nov;4(11):1586–1591. doi: 10.1200/JCO.1986.4.11.1586. [DOI] [PubMed] [Google Scholar]
  18. Lieschke G. J., Maher D., Cebon J., O'Connor M., Green M., Sheridan W., Boyd A., Rallings M., Bonnem E., Metcalf D. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Ann Intern Med. 1989 Mar 1;110(5):357–364. doi: 10.7326/0003-4819-110-5-357. [DOI] [PubMed] [Google Scholar]
  19. McElwain T. J., Hedley D. W., Gordon M. Y., Jarman M., Millar J. L., Pritchard J. High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol. 1979;7 (Suppl 5):360–371. [PubMed] [Google Scholar]
  20. Metcalf D. The granulocyte-macrophage colony-stimulating factors. Science. 1985 Jul 5;229(4708):16–22. doi: 10.1126/science.2990035. [DOI] [PubMed] [Google Scholar]
  21. Morstyn G., Campbell L., Souza L. M., Alton N. K., Keech J., Green M., Sheridan W., Metcalf D., Fox R. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet. 1988 Mar 26;1(8587):667–672. doi: 10.1016/s0140-6736(88)91475-4. [DOI] [PubMed] [Google Scholar]
  22. O'Bryan R. M., Baker L. H., Gottlieb J. E., Rivkin S. E., Balcerzak S. P., Grumet G. N., Salmon S. E., Moon T. E., Hoogstraten B. Dose response evaluation of adriamycin in human neoplasia. Cancer. 1977 May;39(5):1940–1948. doi: 10.1002/1097-0142(197705)39:5<1940::aid-cncr2820390505>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  23. Selby P. J., McElwain T. J., Nandi A. C., Perren T. J., Powles R. L., Tillyer C. R., Osborne R. J., Slevin M. L., Malpas J. S. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol. 1987 May;66(1):55–62. doi: 10.1111/j.1365-2141.1987.tb06890.x. [DOI] [PubMed] [Google Scholar]
  24. Steward W. P., Scarffe J. H., Austin R., Bonnem E., Thatcher N., Morgenstern G., Crowther D. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study. Br J Cancer. 1989 Jan;59(1):142–145. doi: 10.1038/bjc.1989.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Vadhan-Raj S., Keating M., LeMaistre A., Hittelman W. N., McCredie K., Trujillo J. M., Broxmeyer H. E., Henney C., Gutterman J. U. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987 Dec 17;317(25):1545–1552. doi: 10.1056/NEJM198712173172501. [DOI] [PubMed] [Google Scholar]
  26. Vincent M. D., Powles T. J., Coombes R. C., McElwain T. J. Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy. Cancer Chemother Pharmacol. 1988;21(3):255–260. doi: 10.1007/BF00262781. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES